Comparative Pharmacology
Head-to-head clinical analysis: BUTABARBITAL SODIUM versus SODIUM BUTABARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARBITAL SODIUM versus SODIUM BUTABARBITAL.
BUTABARBITAL SODIUM vs SODIUM BUTABARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing CNS depression.
Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.
50-100 mg orally or intramuscularly 3-4 times daily as a sedative; 100-200 mg orally or intramuscularly for preoperative sedation.
None Documented
None Documented
Terminal elimination half-life: 30-50 hours; accumulates with repeated dosing, prolonged in hepatic impairment
Terminal elimination half-life 40-60 hours in adults; prolonged in hepatic impairment and elderly.
Renal: 50-70% as metabolites (hydroxylated and conjugated forms), 5-10% unchanged; fecal: minor (<5%)
Renal excretion of unchanged drug and metabolites; approximately 30-50% as unchanged drug in urine. Minor fecal elimination (<5%).
Category C
Category C
Barbiturate
Barbiturate